STOCK TITAN
  1. Home
  2. News
  3. DVAX

Dynavax Technologies Corp. - DVAX STOCK NEWS

Welcome to our dedicated news page for Dynavax Technologies (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dynavax Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dynavax Technologies's position in the market.

News
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Rhea-AI Summary
Dynavax Technologies (DVAX) will report its first quarter 2024 financial results on May 8, 2024, after the U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT. Participants can access the webcast through the 'Events & Presentations' page on the Company's website. A replay will be available for 30 days. To join the call, participants need to register using the caller registration link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
conferences earnings
-
News
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) to present at TD Cowen's 44th Annual Health Care Conference on March 4, 2024, at 10:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
News
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) reports a strong financial performance for the fourth quarter and full year 2023, with HEPLISAV-B vaccine net product revenue growing by 69% year-over-year to $213 million. Achieving market leader status in key segments and expecting a revenue of $265 - $280 million in 2024, the company is well-positioned for growth and innovation in the vaccine market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
earnings
News
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) will report its Q4 and full year 2023 financial results on February 22, 2024, after the U.S. financial markets close. The company will also host a conference call and live audio webcast on the same day. The live audio webcast can be accessed through the 'Events & Presentations' page on the 'Investors' section of the Company's website. A replay of the webcast will be available for 30 days. Participants can register for the call using the caller registration link and are recommended to dial in or log into the webcast 10 minutes prior to the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences earnings
-
News
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) reports a 69% year-over-year increase in HEPLISAV-B vaccine net product revenue to approximately $213 million for the full year 2023. The company also saw significant gains in HEPLISAV-B market share in the U.S., with total market share increasing to approximately 44% compared to approximately 35% at the end of 2022. Cash, cash equivalents, and marketable securities at year-end increased to approximately $742 million, with the expectation to be cash flow positive for the full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
none
-
News
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
News
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) will present at the 6th Annual Evercore ISI HealthCONx Conference on November 28. The company, a biopharmaceutical firm focusing on innovative vaccines, will webcast the presentation accessible through its Investors website section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences
-
News
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) reported Q3 2023 financial results, with HEPLISAV-B vaccine net product revenue of $62.3 million, a 66% YoY increase. They raised their full-year revenue guidance to $210 - $220 million. Cash and investments increased to $720 million. They are focused on advancing their pipeline of innovative vaccine candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
earnings
-
News
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
Rhea-AI Summary
Dynavax Technologies Corporation will report its third quarter 2023 financial results on November 2, 2023, after the U.S. financial markets close. The company will host a conference call and live audio webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences earnings
News
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Rhea-AI Summary
Dynavax to present at H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
Stock DVAX logo
Dynavax Technologies Corp.

Nasdaq:DVAX

DVAX Rankings

#2131 Ranked by Market Cap
#791 Ranked by Stock Gains
N/A Ranked by Dividends

DVAX Stock Data

1.55B
123.09M
0.31%
98.02%
13.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Emeryville

About DVAX

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.